GlassScriptPhysician profile
Peter Alexander Kouvatsos
NPI 1053570531
$5,767.77
in general payments reported to CMS, 2019-2025
38 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,264 · 2020: $2,286 · 2021: $750 · 2022: $104 · 2023: $157 · 2024: $89.17 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.07 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $637.81 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.13 | 2019-2021 | |
| Novo Nordisk INC | $438.93 | 2019-2021 | |
| Pfizer INC. | $395.51 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $384.63 | 2019-2021 | |
| Astellas Pharma US INC | $363.13 | 2019-2025 | Veozah |
| Abbvie INC. | $360.49 | 2019-2025 | |
| Amarin Pharma, INC. | $302.17 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $244.51 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $227.67 | 2019-2020 | |
| Lilly USA, LLC | $214.95 | 2019-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $201.12 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.61 | 2019-2020 | |
| Amgen INC. | $178.89 | 2019-2021 | |
| Allergan, INC. | $174.04 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $162.28 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $158.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.63 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $66.35 | 2019-2020 | |
| Medtronic, INC. | $60.56 | 2025 | Inceptiv |
| Daiichi Sankyo INC. | $54.37 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $41.39 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $36.64 | 2024 | Quviviq |
| Ironwood Pharmaceuticals, INC | $35.82 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $33.48 | 2020-2021 | |
| Shield Therapeutics INC | $29.87 | 2024 | |
| Philips North America LLC | $28.63 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $28.07 | 2019-2020 | |
| Mylan Specialty L.P. | $24.05 | 2020 | |
| Mannkind Corporation | $23.85 | 2019-2020 | |
| Genentech USA, INC. | $19.27 | 2019 | |
| Nabriva Therapeutics, Plc | $16.64 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.14 | 2019 | |
| Almatica Pharma LLC | $16.14 | 2022 | |
| Sanofi Pasteur INC. | $16.07 | 2019 | |
| Eisai INC. | $14.12 | 2020 | |
| Dexcom, INC. | $12.81 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kouvatsos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.